Absci IPO
Absci is a drug discovery company that uses artificial intelligence and synthetic biology to create better antibody drugs. The company's AI-driven approach to drug discovery and its partnerships with major pharmaceutical companies have positioned it as an innovative player in the biotech industry.
Key Facts
| Industry | Biotechnology |
| Founded | 2011 |
| Headquarters | Vancouver, WA |
| Employees | ~200-300 |
| Website | absci.com |
| Funding | Public company (IPO 2021) |
About Absci
Absci operates as a synthetic biology company that combines artificial intelligence with synthetic biology to discover and develop next-generation protein therapeutics. The company's proprietary platform integrates AI-driven protein design with high-throughput wet lab capabilities to create novel biotherapeutics, including antibodies and other protein-based drugs that would be difficult or impossible to develop through traditional methods.
As a publicly traded company since 2021, Absci has established partnerships with major pharmaceutical companies while also developing its own pipeline of therapeutic candidates. The company's approach represents the convergence of computational biology and traditional drug development, positioning it in the emerging field of AI-driven drug discovery where the ability to design proteins from scratch could unlock new classes of medicines.
IPO Status
Absci went public in July 2021 through a traditional IPO, raising approximately $200 million. The company trades on NASDAQ under the ticker symbol 'ABSI', with shares initially priced at $16 per share. Since going public, Absci has continued to advance its AI-powered drug discovery platform and expand partnerships with pharmaceutical companies. Like many biotech stocks, the share price has experienced volatility reflecting broader market conditions and investor sentiment toward early-stage biotechnology companies focused on platform technologies rather than late-stage drug candidates.
Competitors
Frequently Asked Questions
Does Absci have a stock?
Yes, Absci completed its IPO in July 2021, raising approximately $200 million. The AI-driven drug discovery company now trades on NASDAQ under the ticker symbol 'ABSI'.
When is the Absci IPO date?
Absci already went public in July 2021, so there is no upcoming IPO date. The company completed its initial public offering and began trading on NASDAQ.
How can I buy Absci stock?
You can purchase Absci stock through any major brokerage since it trades publicly on NASDAQ under ticker 'ABSI'. Shares are available for trading during regular market hours through standard investment accounts.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts